Pain Relief Gel Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Pain Relief Gel market size was estimated at USD 10.4 billion in 2023 and is projected to reach USD 15.3 billion in 2030 at a CAGR of 5.2% during the forecast period 2023-2030.

Chronic pain conditions, which include ailments such as arthritis, back pain, and musculoskeletal disorders, are widely prevalent on a global scale. The escalating number of individuals in pursuit of alleviation from the persistent agony that accompanies chronic pain syndromes has resulted in a parallel increase in the demand for pain relief gels, owing to their potential to mitigate the discomfort associated with these conditions.

The world's population is undergoing a process of aging, and this demographic shift has resulted in older adults being increasingly vulnerable to a variety of pain conditions. With the aging population projected to continue growing, there is a corresponding rise in the demand for pain relief products, among which pain relief gels feature prominently. These gels provide a localized and non-invasive approach to pain management, and as such, they are highly favored by many individuals who prefer topical solutions to oral medications. The benefits of using gels are manifold, as they can be applied directly to the affected area, thereby delivering targeted relief and enhancing the therapeutic effects of the treatment.

The current outbreak of COVID-19 is expected to have a substantial impact on the development and progression of the global topical pain relief market. The unprecedented occurrence of the COVID-19 pandemic has placed immense strain on healthcare systems worldwide, resulting in a significant reduction in the number of patient visits to a vast number of clinics and pain services during this period of uncertainty and instability.

Delvens Industry Expert's Standpoint

The demand for products that alleviate pain, specifically gels, is projected to increase due to the escalating prevalence of persistent pain conditions, a burgeoning elderly population, and an uptick in injuries associated with sports. This presents a propitious occasion for producers to meet the demands of an expanded consumer base searching for efficacious pain relief solutions. The consistent undertaking of research and development endeavors may result in the introduction of novel and enhanced formulations for pain relief gels. Advancements such as heightened drug delivery systems, integration of natural constituents, and enhanced potency may set apart products in the market and ensnare consumers searching for more potent and expedient pain relief options. The incidence of injuries that are associated with sports and a lifestyle that is active in nature are among the factors that contribute to the upsurge in the need for gels that are meant to alleviate pain. This need is particularly prominent among athletes, fitness enthusiasts, and individuals who engage in physical activities. These individuals frequently seek out topical solutions that are aimed at mitigating the pain that often arises due to muscle soreness, strains, and sprains.

Market Portfolio

Key Findings

• On the basis of therapeutic class, the segment of non-opioids, which is characterized as drugs that do not exhibit morphine-like effects, is identified as the primary source of revenue and is estimated to experience significant growth during the period of projection. The rationale for this is attributed to its favorable use in comparison to opioid drugs with regards to the treatment of pain that is mild to moderate in nature. Non-opioids are preferred as a treatment option due to the fact that they possess less side effects in comparison to opioids and do not exhibit substance abuse. This preference is further enhanced by the limited number of cases of adverse events that have been reported. Nonetheless, the restricted analgesic effects that non-opioid drugs exhibit implies that their use is limited for the treatment of severe pain. This is a significant limitation that must be considered when selecting a treatment option.

• On the basis of distribution channel, the market encompasses a variety of entities such as pharmacies and drug stores, e-commerce platforms, as well as retail and grocery stores, can be effectively classified into three distinct categories based on their respective operational characteristics. Specifically, it is worth noting that the e-commerce segment is anticipated to showcase remarkable expansion throughout the projected period, which can be attributed to a multitude of factors. These factors include, but are not limited to, the discernible upward trend in the inclination towards the digital acquisition of pharmaceuticals over the more conventional modes of procurement, the heightened cognizance of the virtual pharmacy sphere, and the surge in the number of individuals who possess access to and utilize the internet.
   
• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The North American region has emerged as the predominant market for pain relief gel, primarily owing to the escalating aging population in this region. Additionally, the burgeoning investment in healthcare infrastructure has further contributed to the substantial growth of this market.

Regional Analysis

North America to Dominate the Market

• The North American region has emerged as the predominant market for pain relief gel, primarily owing to the escalating aging population in this region. Additionally, the burgeoning investment in healthcare infrastructure has further contributed to the substantial growth of this market.
   
• It is anticipated that the region encompassing Asia and the Pacific shall undergo a noteworthy escalation in terms of growth.

Competitive Landscape

• Nestle S.A.
• Sun Pharmaceutical Industries Ltd.
• AdvaCare Pharma
• Topical BioMedics, Inc.
• Reckitt Benckiser Group Plc.
• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Sanofi S.A.
• Procter & Gamble
• Salonpas
• Biofreeze

Recent Developments

• In January 2023, Deccan Healthcare, a pioneering nutraceutical and cosmeceutical products company, has recently unveiled the QuitPain instant pain relieving ayurvedic gel in Hyderabad. This highly efficacious gel, which is a proprietary blend of Deccan Healthcare Ltd., has been specially crafted to cater to those seeking easy-to-use ayurvedic pain relief solutions for the alleviation of a myriad of aches and pains.
   
• In December 2022, Manx Healthcare, a prominent pharmaceutical company, recently introduced a novel product into the market, namely Reliviate Aches and Joint Pain Relief 0.5% w/w Gel. This innovative gel, which has been meticulously formulated, is specifically designed to alleviate aches and joint pain, thus providing an efficacious solution for individuals suffering from such debilitating conditions.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Pain Relief Gel Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope